A Phase 4 interventional study of tafamidis meglumine in Transthyretin Amyloid Polyneuropathy (ATTR-PN), sponsored by Pfizer. Completed at 9 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-03-12.
Sponsored by Pfizer · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Amyloid Neuropathies, Familial with a site in China — 8 open to participants now, 8 under way, none of them phase 3. Amyloid Neuropathies, Familial · China.
Among the 10 studies in Amyloid Neuropathies, Familial with a site in China, this one is the only one that started in 2021, is one of 2 in phase 4, and was the 1st registered.
188 studies on the registry are indexed under Amyloid Neuropathies, Familial; 94 are open to participants now.
Browse Amyloid Neuropathies, Familial studies →8 of the 10 studies in Amyloid Neuropathies, Familial with a site in China are open now. Recruiting first, the newest first:
Tianjin Medical University · Sites in China
Ages 18+ · Healthy volunteers
Qilu Pharmaceutical Co., Ltd. · Sites in China
Ages 18–80
AstraZeneca · Sites in China, United States, Canada and 3 more countries
Ages 18–130
Tianjin Medical University · Sites in China
Ages 18–80 · Healthy volunteers
First Hospital of China Medical University · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 69 Amyloid Neuropathies, Familial studies recruiting now, 53 (77%) set no upper age limit and 1 (1%) stops at 75 or younger; 7 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 1 started in 2021.
This study's enrollment of 15 is below the median of 54 across 90 interventional studies indexed under Amyloid Neuropathies, Familial.
Median enrollment 15 across the 3 interventional studies, 500 across the 7 observational. Of the 1 that completed or were terminated, 1 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 10 have an industry lead sponsor. The 9 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Pfizer has 9 studies filed under Amyloid Neuropathies, Familial — fewer than ten, so there is no comparison to draw.
1 of the studies in Amyloid Neuropathies, Familial with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07750678GenEditBio LimitedSafety and Efficacy Study of GEB-101 Injection in Subjects With TGFBI-related Corneal Dystrophy | 2027-08 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Amyloid Neuropathies, Familial with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a single-arm, open-label, multicenter study designed to evaluate the efficacy, safety, tolerability as well as pharmacodynamics of tafamidis meglumine in ATTR-PN participants in China.
Approximately 10-15 participants are planned to be enrolled. All enrolled participants will receive oral tafamidis meglumine 20 mg soft capsules once daily for 72 weeks (18 months).
This is a single-arm, open-label, multicenter study designed to evaluate the efficacy, safety, tolerability as well as pharmacodynamics of tafamidis meglumine in ATTR-PN participants in China.
All enrolled participants will receive oral tafamidis meglumine 20 mg soft capsules once daily starting on Day 1. Clinical visits will be scheduled at Baseline (Day 1) and at Week 4, Week 8, Week 12, Week 24, Week 36, Week 48, Week 60 and Week 72. At Week 36 and Week 60 site visit, assessment of adverse events, safety related lab testings, concomitant medications and investigational product compliance will be scheduled. Every 6 weeks (do not exceed 7 weeks since last confirmation) telephone contacts will be made during visits in which no investigative site visits are scheduled for assessment of adverse events, concomitant medications and investigational product compliance (between Week 12 and 24, between Week 24 and 36, between Week 36 and 48, between Week 48 and 60, and between Week 60 and 72).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Use of diflunisal, tauroursodeoxycholate, doxycycline, inotersen, patisiran or any other TTR stabilizing agent, or experimental interventions for familial amyloidosis within 30 days prior to the study entry and/or during study participation. Participants who are taking or who have previously taken tafamidis.
Prior/Concurrent Clinical Study Experience:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chinese patients diagnosed with ATTR-PN treated with tafamidis 20mg once daily oral administration for 72 weeks (18 months).
Drug: tafamidis meglumine
Tafamidis meglumine 20 mg, once daily, oral administration, for 72 weeks (18 months).
Also known as: Vyndaqel
Change From Baseline in Neuropathy Impairment Score-lower Limb (NIS-LL) Total Score at Week 72
NIS-LL: assess muscle weakness, reflexes, sensation; scored separately for left and right limbs. Components of muscle weakness (hip and knee flexion, hip and knee extension, ankle dorsiflexors, ankle plantar flexors, toe extensors, toe flexors) scored on scale 0 (normal) to 4 (paralysis), higher score=greater weakness. Components of reflexes (quadriceps femoris, triceps surae); sensation (touch pressure, pin-prick, vibration, joint position) scored 0 = normal, 1 = decreased, or 2 = absent. Total possible NIS-LL score range 0-88, high score = more impairment. Components of muscle weakness are scored to eight levels: 0 = Normal, 1 = 25% Weak, 2 = 50% Weak, 3 = 75% Weak, 3.25 = Move against gravity, 3.5 = Movement, gravity eliminated, 3.75 = Muscle flicker, no movement, 4 = Paralysis.
Time frame: Baseline, Week 72
Change From Baseline in Neuropathy Impairment Score-lower Limb (NIS-LL) Total Score at Weeks 24, and 48
NIS-LL: assess muscle weakness, reflexes, sensation; scored separately for left and right limbs. Components of muscle weakness (hip and knee flexion, hip and knee extension, ankle dorsiflexors, ankle plantar flexors, toe extensors, toe flexors) scored on scale 0 (normal) to 4 (paralysis), higher score=greater weakness. Components of reflexes (quadriceps femoris, triceps surae); sensation (touch pressure, pin-prick, vibration, joint position) scored 0 = normal, 1 = decreased, or 2 = absent. Total possible NIS-LL score range 0-88, high score = more impairment. Components of muscle weakness are scored to eight levels: 0 = Normal, 1 = 25% Weak, 2 = 50% Weak, 3 = 75% Weak, 3.25 = Move against gravity, 3.5 = Movement, gravity eliminated, 3.75 = Muscle flicker, no movement, 4 = Paralysis.
Time frame: Baseline, Week 24, Week 48
Change From Baseline in Total Quality of Life (TQOL) of Norfolk Quality of Life - Diabetic Neuropathy (Norfolk QOL-DN) at Weeks 24, 48, and 72
Norfolk QOL-DN: 35-item participant-rated questionnaire assess the impact of neuropathy on the quality of life of participants diagnosed with transthyretin amyloid (ATTR). Scoring is based on 35 questions that yield a TQOL as well as 5 subscale scores: activities of daily living, large fiber neuropathy/physical functioning, small fiber neuropathy, autonomic neuropathy, and symptoms. TQOL= sum of all the items, total possible score range= -2 to 138, where higher score=worse quality of life.
Time frame: Baseline, Week 24, Week 48, Week 72
Change From Baseline in 5 Domains of Norfolk QOL-DN at Weeks 24, 48, and 72
Norfolk QOL-DN: 35-item participant-rated questionnaire assess the impact of neuropathy on the quality of life of participants diagnosed with transthyretin amyloid (ATTR). It is summarized in 5 domains: (1) Activities of daily living (score ranges from 0 to 20, where higher score=worse quality of life); (2) Large fiber neuropathy/physical functioning (score ranges from -2 to 58, where higher score=worse condition); (3) Small fiber neuropathy (score ranges from 0 to 16, where higher score=worse condition); (4) Autonomic neuropathy (score ranges from 0 to 12, where higher score=worse condition) and (5) Symptoms (score ranges from 0 to 32, where higher score=less symptoms of disease). Total possible score range= -2 to 138, where higher score=worse quality of life.
Time frame: Baseline, Week 24, Week 48, Week 72
Change From Baseline in Modified Body Mass Index (mBMI) at Weeks 4, 8, 12, 24, 36, 48, and 72
BMI is calculated by weight divided by height squared and measured as kilogram per square meter (kg/m\^2). mBMI is calculated by multiplying BMI by serum albumin levels \[gram/liter (g/L)\]. mBMI is measured as kg/m\^2\*g/L. A progressive decline in mBMI indicates worsening of disease severity.
Time frame: Baseline, Weeks 4, 8, 12, 24, 36, 48, and 72
Change From Baseline in Physical Component Summary and Mental Component Summary of 36-Item Short Form Survey (SF-36) at Weeks 24, 48, and 72
The SF-36 is a participant administered scale assessing general quality of life. It consists of self-administered 36-item questionnaire that measured 8 health domains: physical function, role-physical, bodily pain, general health, vitality, social function, role-emotional, and mental health. These 8 domains are also summarized as physical and mental component scores. The score for each domain and component score is the mean of the individual question scores, which are scaled from 0 (minimum) to 100 (maximum), where high scores in each dimension and high overall scores indicate a better quality of life.
Time frame: Baseline, Weeks 24, 48, and 72
Change From Baseline in EuroQoL 5 Dimensions 5 Levels (EQ-5D-5L) Index Score at Weeks 24, 48, and 72
EQ-5D-5L: standardized participant (aged \>17 years) completed questionnaire consists of 2 components: a health state profile and an optional VAS. EQ-5D health state profile has 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: 1= no problems, 2= slight problems, 3= moderate problems, 4= severe problems, and 5= extreme problems. Responses to 5 dimensions comprise a health state/a single utility index value. E.g. if a participant responds "no problems" for each 5 dimensions, then health state was coded as "11111" with a predefined index value to it. Every health state (coded as combination of responses on each of 5 dimensions) has a unique predefined utility index value assigned to it, by EuroQol. Chinese value sets (with all possible health states) is used for adults in the study, range from -0.391 to 1. Higher (positive) scores = better health state.
Time frame: Baseline, Weeks 24, 48, and 72
Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs)
An adverse event is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Treatment emergent adverse event is defined as any adverse event started after the first dose. The TEAEs were collected until Week 77.
Time frame: Baseline up to Week 77
Number of Participants With Categorical Vital Signs Data
Vital signs categorical criteria: 1) pulse rate \<40 beats per minute (bpm), or \>120 bpm; 2) standing diastolic blood pressure (BP) \<50 mmHg, or increase ≥20 mmHg, or decrease ≥20 mmHg; 3) standing systolic BP \<90 mmHg, or increase ≥30 mmHg, or decrease ≥30 mmHg; 4) supine diastolic BP \<50 mmHg, or increase ≥20 mmHg, or decrease ≥20 mmHg; 5) supine systolic BP \<90 mmHg, or increase ≥30 mmHg, or decrease ≥30 mmHg.
Time frame: Baseline up to Week 72
Number of Participants With Categorical Electrocardiogram (ECG) Data
ECG categorical criteria: 1) ECG mean heart rate \<40 beats/minute, or \>120 beats/minute; 2) PR interval not otherwise specified ≥300 milliseconds (msec), or baseline \>200 msec and %increase ≥25%/ baseline ≤200 msec and %increase ≥50% (% change ≥25/50%); 3) QRS interval not otherwise specified ≥140 msec, or %change ≥50%; 4) QT interval not otherwise specified ≥500 msec; 5) corrected QT (QTc) interval not otherwise specified ≥450 and \<480 msec, or ≥480 and \<500 msec, or ≥500 msec; or change ≥30 and \<60 msec, or change ≥60 msec.
Time frame: Baseline up to Week 72
Number of Participants With Clinically Significant Echocardiography (ECHO) Value Related to Primary Diagnosis (Transthyretin Amyloidosis [ATTR]) at Baseline, Weeks 24, 48, and 72
Clinically significant ECHO findings include: left ventricular (LV) posterior wall thickness greater than or equal to (\>=)13 mm, LV septal thickness \>= 13 mm, right ventricular thickness \>= 7 mm, ratio of peak mitral early diastolic and atrial contraction velocity (E/A ratio) \>= 2, prime septal (E/E) \>15, ejection fraction \< 50 percent (%), E deceleration time \<= 150 millisecond (ms), isovolumic relaxation time (IVRT) \<= 70 ms, any valve thickening (\> trace regurgitation in mitral, aortic, pulmonary, or tricuspid valves), abnormal respiratory variation of inferior vena cava, pericardial effusion.
Time frame: Baseline, Weeks 24, 48, and 72
Number of Participants With Clinical Laboratory Abnormalities
Protocol-required safety laboratory assessments include: Lymphocytes \<0.8 × LLN; Neutrophils \<0.8 × LLN, or \>1.2 × ULN; Basophils \>1.2 × ULN; Activated Partial Thromboplastin Time \>1.1 × ULN; Prothrombin Time \>1.1 × ULN; Prothrombin International Normalized Ratio \>1.1 × ULN; Bilirubin \>1.5 × ULN; Urate \> 1.2 × ULN; Cholesterol \>1.3 × ULN; Potassium \<0.9 × LLN; Phosphate \>1.2 × ULN; Bicarbonate \>1.1 × ULN; Thyroid Stimulating Hormone \>1.2 × ULN; URINE Protein ≥1; URINE Hemoglobin ≥1; Nitrite ≥1; URINE Erythrocytes ≥20; Epithelial Cells ≥6; and Casts \>1.
Time frame: Baseline up to Week 72
Transthyretin (TTR) Concentrations on Day 1 (Baseline), and at Weeks 8, 12, 24, 48, and 72
The TTR (also referred to as pre-albumin) concentrations were determined as pharmacodynamic (PD) biomarkers.
Time frame: Baseline, Weeks 8, 12, 24, 48, and 72
TTR Stabilization and Percentage and 95% CI of Responders in TTR Stabilization at Post Baseline Visit
The Fraction of Initial (FOI) is the ratio of the measured TTR tetramer concentration (post-denaturation) to the measured TTR concentration (pre-denaturation). Percent Stabilization (%) is the difference between the dosed FOI and the baseline FOI expressed as a percentage of the baseline FOI. Responder was the participant who achieved TTR stabilization (ie, who had been TTR stabilized). Percentage of responders was number of responders / number of evaluable (i.e., analyzed) participants.
Time frame: Weeks 8, 12, 24, 48, and 72
| Milestone | Tafamidis Meglumine 20 mg Once Daily (QD) |
|---|---|
| Started | 15 |
| Completed | 15 |
| Not completed | 0 |
| Milestone | Tafamidis Meglumine 20 mg Once Daily (QD) |
|---|---|
| Started | 15 |
| Completed | 15 |
| Not completed | 0 |
NIS-LL: assess muscle weakness, reflexes, sensation; scored separately for left and right limbs. Components of muscle weakness (hip and knee flexion, hip and knee extension, ankle dorsiflexors, ankle plantar flexors, toe extensors, toe flexors) scored on scale 0 (normal) to 4 (paralysis), higher score=greater weakness. Components of reflexes (quadriceps femoris, triceps surae); sensation (touch pressure, pin-prick, vibration, joint position) scored 0 = normal, 1 = decreased, or 2 = absent. Total possible NIS-LL score range 0-88, high score = more impairment. Components of muscle weakness are scored to eight levels: 0 = Normal, 1 = 25% Weak, 2 = 50% Weak, 3 = 75% Weak, 3.25 = Move against gravity, 3.5 = Movement, gravity eliminated, 3.75 = Muscle flicker, no movement, 4 = Paralysis.
| Units on a scale | Tafamidis Meglumine 20 mg Once Daily (QD) |
|---|---|
| Change From Baseline in Neuropathy Impairment Score-lower Limb (NIS-LL) Total Score at Week 72 | 2.3 (-3.0 to 46.0) |
NIS-LL: assess muscle weakness, reflexes, sensation; scored separately for left and right limbs. Components of muscle weakness (hip and knee flexion, hip and knee extension, ankle dorsiflexors, ankle plantar flexors, toe extensors, toe flexors) scored on scale 0 (normal) to 4 (paralysis), higher score=greater weakness. Components of reflexes (quadriceps femoris, triceps surae); sensation (touch pressure, pin-prick, vibration, joint position) scored 0 = normal, 1 = decreased, or 2 = absent. Total possible NIS-LL score range 0-88, high score = more impairment. Components of muscle weakness are scored to eight levels: 0 = Normal, 1 = 25% Weak, 2 = 50% Weak, 3 = 75% Weak, 3.25 = Move against gravity, 3.5 = Movement, gravity eliminated, 3.75 = Muscle flicker, no movement, 4 = Paralysis.
| Units on a scale | Tafamidis Meglumine 20 mg Once Daily (QD) |
|---|---|
| Change From Baseline in Neuropathy Impairment Score-lower limb (NIS-LL) Total Score at Week 24 | 3.0 (-20.0 to 20.0) |
| Change From Baseline in Neuropathy Impairment Score-lower limb (NIS-LL) Total Score at Week 48 | 8.0 (-13.5 to 18.0) |
Norfolk QOL-DN: 35-item participant-rated questionnaire assess the impact of neuropathy on the quality of life of participants diagnosed with transthyretin amyloid (ATTR). Scoring is based on 35 questions that yield a TQOL as well as 5 subscale scores: activities of daily living, large fiber neuropathy/physical functioning, small fiber neuropathy, autonomic neuropathy, and symptoms. TQOL= sum of all the items, total possible score range= -2 to 138, where higher score=worse quality of life.
| Units on a scale | Tafamidis Meglumine 20 mg Once Daily (QD) |
|---|---|
| Change From Baseline in TQOL of Norfolk QOL-DN at Week 24 | -1.00 (-26.00 to 54.00) |
| Change From Baseline in TQOL of Norfolk QOL-DN at Week 48 | 2.00 (-26.00 to 63.00) |
| Change From Baseline in TQOL of Norfolk QOL-DN at Week 72 | 8.00 (-11.00 to 74.00) |
Norfolk QOL-DN: 35-item participant-rated questionnaire assess the impact of neuropathy on the quality of life of participants diagnosed with transthyretin amyloid (ATTR). It is summarized in 5 domains: (1) Activities of daily living (score ranges from 0 to 20, where higher score=worse quality of life); (2) Large fiber neuropathy/physical functioning (score ranges from -2 to 58, where higher score=worse condition); (3) Small fiber neuropathy (score ranges from 0 to 16, where higher score=worse condition); (4) Autonomic neuropathy (score ranges from 0 to 12, where higher score=worse condition) and (5) Symptoms (score ranges from 0 to 32, where higher score=less symptoms of disease). Total possible score range= -2 to 138, where higher score=worse quality of life.
| Units on a scale | Tafamidis Meglumine 20 mg Once Daily (QD) |
|---|---|
| Change From Baseline in Physical Functioning/Large Fiber Domain of Norfolk QOL-DN at Week 24 | -3.00 (-22.00 to 28.00) |
| Change From Baseline in Physical Functioning/Large Fiber Domain of Norfolk QOL-DN at Week 48 | 2.00 (-13.00 to 38.00) |
| Change From Baseline in Physical Functioning/Large Fiber Domain of Norfolk QOL-DN at Week 72 | 4.00 (-10.00 to 39.00) |
| Change From Baseline in Activities of Daily Living Domain of Norfolk QOL-DN at Week 24 | 0.00 (-4.00 to 12.00) |
| Change From Baseline in Activities of Daily Living Domain of Norfolk QOL-DN at Week 48 | 1.00 (-4.00 to 15.00) |
| Change From Baseline in Activities of Daily Living Domain of Norfolk QOL-DN at Week 72 | 3.00 (-2.00 to 15.00) |
| Change From Baseline in Symptoms Domain of Norfolk QOL-DN at Week 24 | 1.00 (-13.00 to 9.00) |
| Change From Baseline in Symptoms Domain of Norfolk QOL-DN at Week 48 | 2.00 (-6.00 to 9.00) |
| Change From Baseline in Symptoms Domain of Norfolk QOL-DN at Week 72 | 2.00 (-2.00 to 23.00) |
| Change From Baseline in Small Fiber Domain of Norfolk QOL-DN at Week 24 | 0.00 (-3.00 to 6.00) |
| Change From Baseline in Small Fiber Domain of Norfolk QOL-DN at Week 48 | 1.00 (-2.00 to 9.00) |
| Change From Baseline in Small Fiber Domain of Norfolk QOL-DN at Week 72 | 3.00 (-3.00 to 10.00) |
| Change From Baseline in Autonomic Domain of Norfolk QOL-DN at Week 24 | 0.00 (-4.00 to 3.00) |
| Change From Baseline in Autonomic Domain of Norfolk QOL-DN at Week 48 | 0.00 (-5.00 to 4.00) |
| Change From Baseline in Autonomic Domain of Norfolk QOL-DN at Week 72 | 2.00 (-5.00 to 6.00) |
BMI is calculated by weight divided by height squared and measured as kilogram per square meter (kg/m\^2). mBMI is calculated by multiplying BMI by serum albumin levels \[gram/liter (g/L)\]. mBMI is measured as kg/m\^2\*g/L. A progressive decline in mBMI indicates worsening of disease severity.
| kg/m^2*g/L | Tafamidis Meglumine 20 mg Once Daily (QD) |
|---|---|
| Change From Baseline in mBMI at Week 4 | -5.9 (-87.2 to 95.5) |
| Change From Baseline in Modified Body Mass Index (mBMI) at Week 8 | 22.3 (-101.2 to 219.7) |
| Change From Baseline in Modified Body Mass Index (mBMI) at Week 12 | 9.2 (-39.0 to 199.3) |
| Change From Baseline in Modified Body Mass Index (mBMI) at Week 24 | 21.8 (-132.8 to 179.1) |
| Change From Baseline in Modified Body Mass Index (mBMI) at Week 36 | 37.0 (-79.3 to 207.7) |
| Change From Baseline in Modified Body Mass Index (mBMI) at Week 48 | 41.4 (-130.2 to 152.6) |
| Change From Baseline in Modified Body Mass Index (mBMI) at Week 72 | 9.4 (-161.8 to 179.5) |
The SF-36 is a participant administered scale assessing general quality of life. It consists of self-administered 36-item questionnaire that measured 8 health domains: physical function, role-physical, bodily pain, general health, vitality, social function, role-emotional, and mental health. These 8 domains are also summarized as physical and mental component scores. The score for each domain and component score is the mean of the individual question scores, which are scaled from 0 (minimum) to 100 (maximum), where high scores in each dimension and high overall scores indicate a better quality of life.
| Units on a scale | Tafamidis Meglumine 20 mg Once Daily (QD) |
|---|---|
| Change from Baseline in Physical Component Summary at Week 24 | -2.15 (-9.29 to 11.84) |
| Change from Baseline in Physical Component Summary at Week 48 | -0.12 (-12.13 to 12.08) |
| Change from Baseline in Physical Component Summary at Week 72 | -1.60 (-17.61 to 8.89) |
| Change from Baseline in Mental Component Summary at Week 24 | 1.21 (-9.56 to 19.30) |
| Change from Baseline in Mental Component Summary at Week 48 | -2.56 (-31.69 to 9.36) |
| Change from Baseline in Mental Component Summary at Week 72 | -6.10 (-31.85 to 8.17) |
EQ-5D-5L: standardized participant (aged \>17 years) completed questionnaire consists of 2 components: a health state profile and an optional VAS. EQ-5D health state profile has 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: 1= no problems, 2= slight problems, 3= moderate problems, 4= severe problems, and 5= extreme problems. Responses to 5 dimensions comprise a health state/a single utility index value. E.g. if a participant responds "no problems" for each 5 dimensions, then health state was coded as "11111" with a predefined index value to it. Every health state (coded as combination of responses on each of 5 dimensions) has a unique predefined utility index value assigned to it, by EuroQol. Chinese value sets (with all possible health states) is used for adults in the study, range from -0.391 to 1. Higher (positive) scores = better health state.
| Units on a scale | Tafamidis Meglumine 20 mg Once Daily (QD) |
|---|---|
| Change from Baseline in EQ-5D-5L Index Score at Week 24 | 0.00 (-0.50 to 0.22) |
| Change from Baseline in EQ-5D-5L Index Score at Week 48 | -0.05 (-0.51 to 0.11) |
| Change from Baseline in EQ-5D-5L Index Score at Week 72 | -0.16 (-0.75 to 0.11) |
An adverse event is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Treatment emergent adverse event is defined as any adverse event started after the first dose. The TEAEs were collected until Week 77.
| Participants | Tafamidis Meglumine 20 mg Once Daily (QD) |
|---|---|
| Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) | 13 |
Vital signs categorical criteria: 1) pulse rate \<40 beats per minute (bpm), or \>120 bpm; 2) standing diastolic blood pressure (BP) \<50 mmHg, or increase ≥20 mmHg, or decrease ≥20 mmHg; 3) standing systolic BP \<90 mmHg, or increase ≥30 mmHg, or decrease ≥30 mmHg; 4) supine diastolic BP \<50 mmHg, or increase ≥20 mmHg, or decrease ≥20 mmHg; 5) supine systolic BP \<90 mmHg, or increase ≥30 mmHg, or decrease ≥30 mmHg.
| Participants | Tafamidis Meglumine 20 mg Once Daily (QD) |
|---|---|
| Pulse rate <40 bpm | 0 |
| Pulse rate >120 bpm | 0 |
| Standing diastolic BP <50 mmHg | 4 |
| Standing diastolic BP increase ≥20 mmHg | 3 |
| Standing diastolic BP decrease ≥20 mmHg | 0 |
| Standing systolic BP <90 mmHg | 6 |
| Standing systolic BP increase ≥30 mmHg | 5 |
| Standing systolic BP decrease ≥30 mmHg | 3 |
| Supine diastolic BP <50 mmHg | 0 |
| Supine diastolic BP increase ≥20 mmHg | 2 |
| Supine diastolic BP decrease ≥20 mmHg | 2 |
| Supine systolic BP <90 mmHg | 0 |
| Supine systolic BP increase ≥30 mmHg | 1 |
| Supine systolic BP decrease ≥30 mmHg | 1 |
ECG categorical criteria: 1) ECG mean heart rate \<40 beats/minute, or \>120 beats/minute; 2) PR interval not otherwise specified ≥300 milliseconds (msec), or baseline \>200 msec and %increase ≥25%/ baseline ≤200 msec and %increase ≥50% (% change ≥25/50%); 3) QRS interval not otherwise specified ≥140 msec, or %change ≥50%; 4) QT interval not otherwise specified ≥500 msec; 5) corrected QT (QTc) interval not otherwise specified ≥450 and \<480 msec, or ≥480 and \<500 msec, or ≥500 msec; or change ≥30 and \<60 msec, or change ≥60 msec.
| Participants | Tafamidis Meglumine 20 mg Once Daily (QD) |
|---|---|
| ECG mean heart rate <40 beats/minute | 0 |
| ECG mean heart rate >120 beats/minute | 0 |
| PR interval not otherwise specified ≥300 milliseconds (msec) | 0 |
| PR interval not otherwise specified % change ≥25/50% | 0 |
| QRS interval not otherwise specified ≥140 msec | 1 |
| QRS interval not otherwise specified %change ≥50% | 1 |
| QT interval not otherwise specified ≥500 msec | 0 |
| corrected QT (QTc) interval not otherwise specified ≥450 and <480 msec | 9 |
| corrected QT (QTc) interval not otherwise specified ≥480 and <500 msec | 7 |
| corrected QT (QTc) interval not otherwise specified ≥500 msec | 3 |
| corrected QT (QTc) interval not otherwise specified change ≥30 and <60 msec | 5 |
| corrected QT (QTc) interval not otherwise specified change ≥60 msec | 1 |
Clinically significant ECHO findings include: left ventricular (LV) posterior wall thickness greater than or equal to (\>=)13 mm, LV septal thickness \>= 13 mm, right ventricular thickness \>= 7 mm, ratio of peak mitral early diastolic and atrial contraction velocity (E/A ratio) \>= 2, prime septal (E/E) \>15, ejection fraction \< 50 percent (%), E deceleration time \<= 150 millisecond (ms), isovolumic relaxation time (IVRT) \<= 70 ms, any valve thickening (\> trace regurgitation in mitral, aortic, pulmonary, or tricuspid valves), abnormal respiratory variation of inferior vena cava, pericardial effusion.
| Participants | Tafamidis Meglumine 20 mg Once Daily (QD) |
|---|---|
| Number of Participants at Baseline | 9 |
| Number of Participants at Week 24 | 11 |
| Number of Participants at Week 48 | 9 |
| Number of Participants at Week 72 | 10 |
Protocol-required safety laboratory assessments include: Lymphocytes \<0.8 × LLN; Neutrophils \<0.8 × LLN, or \>1.2 × ULN; Basophils \>1.2 × ULN; Activated Partial Thromboplastin Time \>1.1 × ULN; Prothrombin Time \>1.1 × ULN; Prothrombin International Normalized Ratio \>1.1 × ULN; Bilirubin \>1.5 × ULN; Urate \> 1.2 × ULN; Cholesterol \>1.3 × ULN; Potassium \<0.9 × LLN; Phosphate \>1.2 × ULN; Bicarbonate \>1.1 × ULN; Thyroid Stimulating Hormone \>1.2 × ULN; URINE Protein ≥1; URINE Hemoglobin ≥1; Nitrite ≥1; URINE Erythrocytes ≥20; Epithelial Cells ≥6; and Casts \>1.
| Participants | Tafamidis Meglumine 20 mg Once Daily (QD) |
|---|---|
| Number of Participants With Clinical Laboratory Abnormalities | 12 |
The TTR (also referred to as pre-albumin) concentrations were determined as pharmacodynamic (PD) biomarkers.
| Milligrams per deciliter (mg/dL) | Tafamidis Meglumine 20 mg Once Daily (QD) |
|---|---|
| Median and Range of TTR Concentration on Day 1 (baseline) | 18.70 (9.03 to 28.0) |
| Median and Range of TTR Concentration at Week 8 | 23.20 (13.5 to 36.2) |
| Median and Range of TTR Concentration at Week 12 | 28.00 (13.5 to 33.3) |
| Median and Range of TTR Concentration at Week 24 | 25.70 (13.3 to 30.9) |
| Median and Range of TTR Concentration at Week 48 | 27.90 (19.0 to 33.4) |
| Median and Range of TTR Concentration at Week 72 | 26.60 (14.4 to 32.2) |
The Fraction of Initial (FOI) is the ratio of the measured TTR tetramer concentration (post-denaturation) to the measured TTR concentration (pre-denaturation). Percent Stabilization (%) is the difference between the dosed FOI and the baseline FOI expressed as a percentage of the baseline FOI. Responder was the participant who achieved TTR stabilization (ie, who had been TTR stabilized). Percentage of responders was number of responders / number of evaluable (i.e., analyzed) participants.
| Percentage of participants | Tafamidis Meglumine 20 mg Once Daily (QD) |
|---|---|
| Percentage and 95% CI of Responders in TTR Stabilization at Week 8 | 100.0 (66.4 to 100.0) |
| Percentage and 95% CI of Responders in TTR Stabilization at Week 12 | 100.0 (69.2 to 100.0) |
| Percentage and 95% CI of Responders in transthyretin (TTR) Stabilization at Week 24 | 100.0 (69.2 to 100.0) |
| Percentage and 95% CI of Responders in transthyretin (TTR) Stabilization at Week 48 | 100.0 (54.1 to 100.0) |
| Percentage and 95% CI of Responders in transthyretin (TTR) Stabilization at Week 72 | 87.5 (47.3 to 99.7) |
Collected over Baseline up to Week 77. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tafamidis Meglumine 20 mg Once Daily (QD) | 0/15 (0%) | 3/15 (20%) | 13/15 (86.7%) |
| Event | Tafamidis Meglumine 20 mg Once Daily (QD) |
|---|---|
| AmyloidosisImmune system disorders | 1/15 |
| Femur fractureInjury, poisoning and procedural complications | 1/15 |
| Orthostatic hypotensionVascular disorders | 1/15 |
| Event | Tafamidis Meglumine 20 mg Once Daily (QD) |
|---|---|
| Upper respiratory tract infectionInfections and infestations | 3/15 |
| Urinary tract infectionInfections and infestations | 3/15 |
| FallInjury, poisoning and procedural complications | 3/15 |
| AnaemiaBlood and lymphatic system disorders | 2/15 |
| DiarrhoeaGastrointestinal disorders | 2/15 |
| Blood thyroid stimulating hormone decreasedInvestigations | 2/15 |
| Urinary sediment presentInvestigations | 2/15 |
| White blood cells urine positiveInvestigations | 2/15 |
| HypertriglyceridaemiaMetabolism and nutrition disorders | 2/15 |
| HyperuricaemiaMetabolism and nutrition disorders | 2/15 |
| Age, Continuous(Years) | Tafamidis Meglumine 20 mg Once Daily (QD) |
|---|---|
| Mean | 51.1 ± 15.75 |
| Age, Customized(Participants) | Tafamidis Meglumine 20 mg Once Daily (QD) |
|---|---|
| 18-44 years | 6 |
| 45-64 years | 5 |
| >=65 years | 4 |
| Sex: Female, Male(Participants) | Tafamidis Meglumine 20 mg Once Daily (QD) |
|---|---|
| Female | 5 |
| Male | 10 |
| Ethnicity (NIH/OMB)(Participants) | Tafamidis Meglumine 20 mg Once Daily (QD) |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 15 |
| Unknown or Not Reported | 0 |
| Race/Ethnicity, Customized(Participants) | Tafamidis Meglumine 20 mg Once Daily (QD) |
|---|---|
| Asian | 15 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Apr 2021 to primary completion in Feb 2023, 21 months.
Results were first posted in Mar 2024, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tafamidis
Amyloid Neuropathies, Familial →